Mesutoclax在治疗复发/难治性套细胞淋巴瘤（MCL）、慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 （CLL/SLL）和急性髓系白血病（AML）的研究中，都展现了卓越的有效性和安全性。Mesutoclax治疗 复发/难治性MCL的研究入选口头报告，Mesutoclax治疗CLL/SLL和AML的两项研究入选海报展示。 中证报中证网讯（王珞）12月9日，诺诚健华在其微信公众号宣布，公司自主研发的新型BCL2抑制剂 Mesutoclax（ICP-248）共有三项研究在第67届美国血液学会（ASH）年会上进行了公布。 ...

Core Viewpoint - The 2025 National Medical Insurance Drug List has been officially announced, including the addition of the BTK inhibitor, Oubatinib, for the treatment of CLL/SLL patients, marking a significant development for the company and the industry [1] Group 1: Drug Approval and Inclusion - Oubatinib has been included in the 2025 National Medical Insurance Drug List for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients [1] - The drug has also successfully renewed its indications for previously treated CLL/SLL, mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) [1] - The new drug list will be implemented starting January 1, 2026 [1] Group 2: Company Representation and Innovation - The announcement of the drug list took place during the 2025 Innovative Drug High-Quality Development Conference, where the company showcased its core pipeline and innovative highlights [1] - Oubatinib received approval for its fourth indication in China in April of this year [1]

作为国家"重大新药创制"专项成果，奥布替尼拥有更精准的靶点选择性，对BTK靶点的占有率近 100%；个体间差异小，对其他激酶无明显抑制作用，在确保疗效的同时又有效避免了由于脱靶效应造 成的不良反应。此外，奥布替尼实现了一天一次口服给药，为患者持续治疗带来了方便。 （编辑 郭之宸） 2025年国家医保药品目录在2025创新药高质量发展大会期间发布。作为创新药企业代表，诺诚健华在大 会期间展示了核心管线和创新亮点。 今年4月，奥布替尼获批用于一线治疗CLL/SLL患者，这是奥布替尼在中国获批的第四个适应症。 本报记者 许林艳 12月7日，2025年《国家基本医疗保险、生育保险和工伤保险药品目录》（国家医保药品目录）在广州 正式公布。诺诚健华医药有限公司（以下简称"诺诚健华"）自主研发的布鲁顿酪氨酸激酶（BTK）抑制 剂宜诺凯®（奥布替尼）新增适应症被纳入2025年国家医保药品目录，用于一线治疗慢性淋巴细胞白血 病/小淋巴细胞淋巴瘤（CLL/SLL）患者。与此同时，奥布替尼用于既往至少接受过一种治疗的 CLL/SLL、既往至少接受过一种治疗的套细胞淋巴瘤（MCL）以及既往至少接受过一种治疗的边缘区 淋巴瘤（MZL） ...

今年4月，奥布替尼获批用于一线治疗CLL/SLL患者，这是奥布替尼在中国获批的第四个适应症。 作为国家"重大新药创制"专项成果，奥布替尼拥有更精准的靶点选择性，对BTK靶点的占有率近 100%；个体间差异小，对其他激酶无明显抑制作用，在确保疗效的同时又有效避免了由于脱靶效应造 成的不良反应。此外，奥布替尼实现了一天一次口服给药，为患者持续治疗带来了方便。 12月7日，2025年《国家基本医疗保险、生育保险和工伤保险药品目录》(国家医保药品目录)在广州正 式公布。诺诚健华医药有限公司(以下简称"诺诚健华")自主研发的布鲁顿酪氨酸激酶(BTK)抑制剂宜诺 凯(奥布替尼)新增适应症被纳入2025年国家医保药品目录，用于一线治疗慢性淋巴细胞白血病/小淋巴细 胞淋巴瘤(CLL/SLL)患者。与此同时，奥布替尼用于既往至少接受过一种治疗的CLL/SLL、既往至少接 受过一种治疗的套细胞淋巴瘤(MCL)以及既往至少接受过一种治疗的边缘区淋巴瘤(MZL)三项适应症成 功续约。新版国家医保目录将于2026年1月1日起开始实施。 2025年国家医保药品目录在2025创新药高质量发展大会期间发布。作为创新药企业代表，诺诚健华在大 ...

Core Points - The 2025 National Medical Insurance Drug List was officially announced in Guangzhou on December 7, 2023, including the addition of the BTK inhibitor Ibrutinib (brand name: Aobutini) for the first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients [2] - Aobutini also successfully renewed its indications for previously treated CLL/SLL, Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL) [2] - The new drug list will be implemented starting January 1, 2026, and was released during the 2025 Innovative Drug High-Quality Development Conference [2] Company Highlights - Aobutini was approved for the first-line treatment of CLL/SLL patients in April 2023, marking its fourth indication in China [3] - As a result of the "Major New Drug Creation" initiative, Aobutini has nearly 100% target selectivity for the BTK target, with minimal inter-individual variability and no significant inhibitory effects on other kinases, ensuring efficacy while avoiding adverse reactions due to off-target effects [3] - Aobutini offers the convenience of once-daily oral administration, facilitating continuous treatment for patients [3]

Core Insights - The National Medical Insurance Drug List for 2025 was officially announced, including the addition of the BTK inhibitor, Ibrutinib (Obinutuzumab), for the first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients [1] - Ibrutinib has also successfully renewed its indications for previously treated CLL/SLL, Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL) [1] - The new drug list will be implemented starting January 1, 2026, and was released during the 2025 Innovative Drug High-Quality Development Conference [1] Company Overview - Nocere Biopharma is a commercial-stage biopharmaceutical company focused on developing first-in-class drugs for malignant tumors and autoimmune diseases [3] - The company has multiple new drug products at various stages of commercialization, clinical trials, and preclinical development [3] - Nocere Biopharma has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [3] Product Details - Ibrutinib, as a result of the national "Major New Drug Creation" initiative, has nearly 100% selectivity for the BTK target, with minimal inter-individual variability and no significant inhibition of other kinases [2] - The drug is administered orally once a day, providing convenience for continuous treatment for patients [2]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 《港股公告:证券变动月报表》 截至2025年12月4日收盘，诺诚健华（688428）报收于24.84元，较前一交易日上涨1.89%，最新总市值 为438.34亿元。该股当日开盘24.39元，最高25.13元，最低24.31元，成交额达7773.89万元，换手率为 1.16%。 公司近日发布公告，披露截至2025年11月30日的证券变动月报表。公告显示，诺诚健华医药有限公司法 定股本无变动，已发行股份总数保持不变。其中，香港上市普通股已发行股份为1,493,798,235股，库存 股为2,486,000股；于上海证券交易所科创板上市的人民币普通股为268,359,717股。报告期内无新增或减 少股份。公司存在股权激励计划，包括2023年及2024年人民币股股份激励计划，部分限制性股票已失 效，但本月未发生新股发行或库存股转让。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底法定/註冊 ...

Core Viewpoint - The Hong Kong stock market's innovative drug concept stocks are experiencing a continuous rebound, with notable increases in share prices for several companies [1] Group 1: Company Performance - Gilead Sciences-B has seen a rise of over 9% [1] - WuXi Biologics has increased by more than 6% [1] - Other companies such as Rongchang Biopharmaceutical, Innovent Biologics, and I-Mab have also shown upward movement in their stock prices [1]